GlassScriptPhysician profile
William W Reed
NPI 1790784767
$7,514.45
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,027 · 2020: $266 · 2021: $1,386 · 2022: $2,518 · 2023: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.09 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,137.04 | 2019-2023 | Enbrel, Otezla, Tavneos |
| Lilly USA, LLC | $833.34 | 2019-2023 | Taltz, Mounjaro, Jardiance |
| Abbvie INC. | $772.55 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $626.30 | 2019-2023 | Farxiga, Saphnelo, Evusheld |
| Pfizer INC. | $482.50 | 2019-2023 | |
| Janssen Biotech, INC. | $390.10 | 2019-2023 | Tremfya |
| Novo Nordisk INC | $288.02 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Radius Health, INC. | $270.63 | 2019-2023 | Tymlos |
| Mallinckrodt Hospital Products INC. | $237.80 | 2021-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $224.09 | 2021-2023 | |
| Genentech USA, INC. | $215.29 | 2019-2023 | Actemra |
| Novartis Pharmaceuticals Corporation | $198.88 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $158.36 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Janssen Scientific Affairs, LLC | $149.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $137.01 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.